Introduction and objectives: Ropivacaine is a long-acting local anesthetic that causes prolonged anesthesia and is beneficial for a wide variety of surgeries. Systemic toxicity has been reported after usage of high dose ropivacaine or inadvertent intravascular administration. We report a case of ropivacaine withdrawal, which to our knowledge has not been previously described in the literature. Case report: The patient presented to our department with uncontrolled belt-like upper-abdominal pain, self-rated as a 9/10 on the numeric rating scale. We decided to use continuous epidural analgesia with ropivacaine through a multi-port epidural catheter. Pain was well controlled for one month without significant adverse effects. However, ropivacaine unexpectedly ran out and two hours later the patient developed agitation, generalized tremor, tachycardia, and tachypnea. These symptoms resolved 30 minutes after reinitiating epidural ropivacaine. Discussion: Our hypothesis of ropivacaine withdrawal was related to the timing of symptoms in relation to drug administration over two episodes. The possible mechanism of the observed withdrawal syndrome is upregulation of voltage-gated sodium channels after prolonged inhibition, resulting in increase in sodium influx and genetic variation.

Viderman, D., Portnyagin, I., La Fleur, P., Bilotta, F. (2020). [Ropivacaine withdrawal syndrome: a case report]. BRAZILIAN JOURNAL OF ANESTHESIOLOGY, 70(1), 66-68 [10.1016/j.bjan.2019.12.006].

[Ropivacaine withdrawal syndrome: a case report]

Bilotta, Federico
2020-01-01

Abstract

Introduction and objectives: Ropivacaine is a long-acting local anesthetic that causes prolonged anesthesia and is beneficial for a wide variety of surgeries. Systemic toxicity has been reported after usage of high dose ropivacaine or inadvertent intravascular administration. We report a case of ropivacaine withdrawal, which to our knowledge has not been previously described in the literature. Case report: The patient presented to our department with uncontrolled belt-like upper-abdominal pain, self-rated as a 9/10 on the numeric rating scale. We decided to use continuous epidural analgesia with ropivacaine through a multi-port epidural catheter. Pain was well controlled for one month without significant adverse effects. However, ropivacaine unexpectedly ran out and two hours later the patient developed agitation, generalized tremor, tachycardia, and tachypnea. These symptoms resolved 30 minutes after reinitiating epidural ropivacaine. Discussion: Our hypothesis of ropivacaine withdrawal was related to the timing of symptoms in relation to drug administration over two episodes. The possible mechanism of the observed withdrawal syndrome is upregulation of voltage-gated sodium channels after prolonged inhibition, resulting in increase in sodium influx and genetic variation.
2020
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MEDS-23/A - Anestesiologia
English
Abstinência
Cancer pain
Dor oncológica
Ropivacaine
Ropivacaína
Withdrawal
Viderman, D., Portnyagin, I., La Fleur, P., Bilotta, F. (2020). [Ropivacaine withdrawal syndrome: a case report]. BRAZILIAN JOURNAL OF ANESTHESIOLOGY, 70(1), 66-68 [10.1016/j.bjan.2019.12.006].
Viderman, D; Portnyagin, I; La Fleur, P; Bilotta, F
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
2020 RopiWithdraw-BJAN19.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 309.1 kB
Formato Adobe PDF
309.1 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/461641
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact